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ABSTRACT 
Tumor disease is a main cause of death in Western countries and a most common malignancy is 
colorectal cancer (CRC). Growing tumors are dependent on interactions among several different 
cells as well as signaling pathways. Many tumors display increased expression of the enzyme 
cyclooxygenase-2 (COX-2) in conjunction with changes in tissue levels of prostanoids. However, 
COX-2 expression is usually unevenly distributed among cells in tumor tissue and several cell 
clones display little or no COX-2 expression. A frequent change of prostanoid metabolism in 
CRC is increased PGE2 production, which appears to be involved in several different steps of 
tumor progression. Prostanoids bind to receptors on cell membranes with subsequent activation 
of different intracellular signaling pathways. Therefore, a general aim of this work was to evaluate 
changes in expression of prostanoid receptors and related factors involved in prostanoid 
metabolism in human CRC suggesting possible specific targets for interventions on prostanoid 
metabolism to attenuate progression. This aim was partly performed by analyses with realtime-
PCR of tumor and normal colon tissue samples from human CRC obtained at surgery. Uneven 
distribution of COX-2 expression, as confirmed by IHC, could hypothetically be explained by 
gene silencing following DNA methylation. Therefore, methylation analysis of the COX-2 
promoter was also performed. Furthermore, our patients received short-term pre-operative 
treatment with non-selective COX-inhibition (indomethacin) to evaluate changes in gene 
expression related to prostanoid levels determined by microarray.  
Prostanoid receptor expression was decreased in tumor tissue and reduced concentration of 
prostanoids had no negative effect on tissue expression of most prostanoid receptors. By 
contrast, tumor tissue expression of the EP2 subtype receptor showed negative prediction of 
patient survival. Methylation of COX-2 promoter sequences did not explain the lack of COX-2 
expression in tumor tissue cells. Short-term pre-operative treatment with indomethacin was 
followed by pronounced alterations of gene expression in both tumor and normal colon tissue. 
Several differences in expression of genes known to regulate COX-2 expression, including 
transcriptional factors, occurred in relationship to COX-2 in tumor tissue. Our observations 
suggest that prostanoid metabolism is complex in CRC and involves several hundred genes in 
different cell types. Alterations in prostanoid metabolism was  related to tumor stage progression 
and may offer therapeutical targets in addition to treatment with conventional COX inhibitors 
for chemoprevention of CRC, since such long-term treatment may be associated with 
considerable side effects in patients.   
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